PFKFB3促进腺样囊性癌ACC-2细胞增殖、迁移、侵袭和转移

doi:10.3760/cma.j.issn.1673-422X.2018.10.001

摘要/Abstract

摘要： 目的研究腺样囊性癌中糖酵解限速酶6-磷酸果糖2激酶/果糖-2，6-二磷酸酶3（PFKFB3）的表达水平，及其对腺样囊性癌细胞增殖、迁移、体内成瘤的影响。方法应用免疫组织化学技术和Western blotting检测29例腺样囊性癌和10例癌旁正常唾液腺组织中PFKFB3的表达水平。腺病毒载体沉默腺样囊性癌ACC2细胞中PFKFB3，通过细胞增殖实验、细胞划痕实验、Transwell小室实验、裸鼠移植瘤模型和裸鼠肺转移模型观察PFKFB3沉默对细胞生长、迁移、侵袭、体内成瘤和远处转移的影响。结果免疫组织化学染色结果显示，PFKFB3在腺样囊性癌组织中阳性率为93.1%（27/29），在正常唾液腺中阳性率为20.0%（2/10），差异有统计学意义（χ2=20.84，P＜0.001）。四甲基偶氮唑蓝（MTT）增殖实验结果显示，72 h时，PFKFB3沉默后的腺样囊性癌ACC2（PFKFB3-ACC-2）细胞组吸光度为1.8±0.2，明显低于ACC2细胞组吸光度4.7±0.8，差异具有统计学意义（t=3.582，P=0.001）。细胞划痕实验结果表明，刮除细胞24 h后，PFKFB3-ACC-2细胞组划痕区细胞数量为(99.8±13.2)个，低于ACC2组［(263.0±97.4)个］，差异具有统计学意义（t=2.868，P=0.029）。Transwell小室检测结果发现，24 h时穿过基质胶的PFKFB3-ACC-2细胞数量［（17.6±2.1）个］明显少于ACC2细胞［（28.6±3.8）个］，差异有统计学意义（t=4.452，P=0.004）。PFKFB3-ACC2细胞组肿瘤体积为（623.5±134.1）mm3，明显小于ACC2细胞组肿瘤体积［（1 621.0±278.1）mm3］，差异有统计学意义（t=4.213，P=0.001）。ACC-2细胞组裸鼠肺部转移灶数目为（18.1±3.2）个，明显多于PFKFB3-ACC2细胞组［（4.1±2.2）个，t=6.322，P=0.001］。结论腺样囊性癌组织中PFKFB3表达水平明显高于正常唾液腺组织，且高表达的PFKFB3在腺样囊性癌细胞增殖、迁移、侵袭和转移等生物学行为中起促进作用。

关键词: 癌, 腺样囊性, 糖酵解, PFKFB3, 肿瘤进展

Abstract: Objective To evaluate the expression of 6-phosphofructo-2kinase/fructose-2, 6-bisphosphatase 3 (PFKFB3) in adenoid cystic carcinoma and the effects of PFKFB3 on the proliferation, migration, invasion and tumorigenesis in vivo of adenoid cystic carcinoma cells. Methods Immunohistochemistry and Western blotting were applied to detect the expression of PFKFB3 in 29 cases of adenoid cystic carcinoma tissues and 10 cases of paracarcinoma normal salivary gland tissues. PFKFB3 in adenoid cystic carcinoma ACC2 cells was silenced by adenovirus vector. The effects of PFKFB3 silence on cell proliferation, migration, invasion and tumorigenesis in vivo and distant metastasis of adenoid cystic carcinoma cells were evaluated by cell proliferation assay, wound healing assay, Transwell assay, xenografted mice model and lung metastasis mice model. Results The results of immunohistochemical staining showed that the positive expression rate of PFKFB3 in adenoid cystic carcinoma tissues was 93.1% (27/29), and the positive expression rate of PFKFB3 in normal salivary gland tissues was 20.0% (2/10), with a significant difference (χ2=20.84, P＜0.001). The results of methyl thiazolyl tetrazolium (MTT) assay showed that, compared with ACC2 group, the proliferation activity of cancer cells with silence of PFKFB3 (PFKFB3-ACC-2) was significantly suppressed for 72 h (1.8±0.2 vs. 4.7±0.8, t=3.582, P=0.001). The results of wound healing assay showed that after scraping cells away for 24 h, the number of cells in the scratch area was 99.8±13.2 in the PFKFB3-ACC2 group, which was significantly less than that in the ACC-2 group (263.0±97.4, t=2.868, P=0.029). Transwell results indicated that the number of cells passing through matrigel was 17.6±2.1 in the PFKFB3-ACC-2 group, which was less than that in the ACC-2 group (28.6±3.8, t=4.452, P=0.004). The tumor volume in the PFKFB3-ACC-2 ［(623.5±134.1) mm3］ was smaller than that in the ACC-2 group ［(1 621.0±278.1) mm3, t=4.213, P=0.001］. More pulmonary metastases were found in the ACC-2 group than PFKFB3-ACC-2 group (18.1±3.2 vs. 4.1±2.2, t=6.322, P=0.001). Conclusion The expression of PFKFB3 is higher in adenoid cystic carcinoma tissue than normal salivary gland tissue, and the highly expressed PFKFB3 plays a driving role in the proliferation, migration, invasion and metastasis in adenoid cystic carcinoma.

Key words: Carcinoma, adenoid cystic, Glycolysis, PFKFB3, Tumor development

乔燕,柳鑫. PFKFB3促进腺样囊性癌ACC-2细胞增殖、迁移、侵袭和转移[J]. 国际肿瘤学杂志, 2018, 45(10): 577-582.

Qiao Yan, Liu Xin. PFKFB3 promotes cell proliferation, migration, invasion and metastasis in adenoid cystic carcinoma ACC-2 cells[J]. Journal of International Oncology, 2018, 45(10): 577-582.

参考文献

［1］ Dillon PM, Chakraborty S, Moskaluk CA, et al. Adenoid cystic carcinoma: a review of recent advances, molecular targets and clinical trials［J］. Head Neck, 2016, 38 (4): 620-627. DOI: 10.1002/hed.23925. ［2］黄擎, 韩楠男, 刘胜文, 等. 唾液腺腺样囊性癌颈淋巴结转移规律的临床研究［J］. 中国肿瘤临床, 2016, 43(24): 1094-1098. DOI: 10.3969/j.issn.10008179.2016.24.125. ［3］严斐, 王超, 黎婷, 等. miR21对唾液腺腺样囊性癌细胞增殖和凋亡的影响及机制研究［J］. 中国口腔颌面外科杂志, 2017, 15(3): 209-213. DOI: 10.19438/j.cjoms.2017.03.004. ［4］ Chen W, Cao G, Yuan X, et al. Notch1 knockdown suppresses proliferation, migration and metastasis of salivary adenoid cystic carcinoma cells［J］. J Transl Med, 2015, 13: 167. DOI: 10.1186/s12967-015-0520-2. ［5］梁军, 黄志权, 游云华, 等. HIF1α和VEGF的表达与腺样囊性癌临床病理的相关性研究［J］. 中国口腔颌面外科杂志, 2010, 8(6): 548-554. ［6］ Ali S, Yeo JC, Magos T, et al. Clinical outcomes of adenoid cystic carcinoma of the head and neck: a single institution 20year experience［J］. J Laryngol Otol, 2016, 130 (7): 680-685. DOI: 10.1017/S0022215116008124. ［7］黄应斌, 农晓琳, 杨亦萍, 等. CXCL12/CXCR4在腺样囊性癌中的表达及对预后的价值［J］. 实用口腔医学杂志, 2015, 31(2): 210-214. DOI: 10.3969/j.issn.1001-3733.2015.02.014. ［8］周宇会, 魏九峰, 李国东, 等. Warburg效应在肿瘤中的研究进展［J］. 国际肿瘤学杂志, 2017, 44(10): 762-766. DOI: 10.3760/cma.j.issn.1673422X.2017.10.010. ［9］王豪华, 陈秀星, 郭桂芳. 己糖激酶Ⅱ与肿瘤增殖及靶向治疗［J］. 国际肿瘤学杂志, 2017, 44(3): 213-216. DOI: 10.3760/cma.j.issn.1673422X.2017.03.014. ［10］ Douglas JG, Laramore GE, AustinSeymour M, et al. Treatment of locally advanced adenoid cystic carcinoma of the head and neck with neutron radiotherapy［J］. Int J Radiat Oncol Biol Phys, 2000, 46(3): 551-557. ［11］ Jang S, Patel PN, Kimple RJ, et al. Clinical outcomes and prognostic factors of adenoid cystic carcinoma of the head and neck［J］. Anticancer Res, 2017, 37(6): 3045-3052. DOI: 10.21873/anticanres.11659. ［12］ Bell D, Hanna EY. Head and neck adenoid cystic carcinoma: what is new in biological markers and treatment?［J］. Curr Opin Otolaryngol Head Neck Surg, 2013, 21(2): 124-129. DOI: 10.1097/MOO.0b013e32835c05fd. ［13］ Oldham RK. Cancer biotherapy: more than immunotherapy［J］. Cancer Biother Radiopharm, 2017, 32(4): 111114. DOI: 10.1089/cbr.2017.28999.old. ［14］ Neugent ML, Goodwin J, Sankaranarayanan I, et al. A new perspective on the heterogeneity of cancer glycolysis［J］. Biomol Ther (Seoul), 2018, 26(1): 10-18. DOI: 10.4062/biomolther.2017.210. ［15］ Li HM, Yang JG, Liu ZJ, et al. Blockage of glycolysis by targeting PFKFB3 suppresses tumor growth and metastasis in head and neck squamous cell carcinoma［J］. J Exp Clin Cancer Res, 2017, 36(1): 7. DOI: 10.1186/s13046-016-0481-1. ［16］ Chen L, Zhao J, Tang Q, et al. PFKFB3 control of cancer growth by responding to circadian clock outputs［J］. Sci Rep, 2016, 6: 24324. DOI: 10.1038/srep24324. ［17］ Gu M, Li L, Zhang Z, et al. PFKFB3 promotes proliferation, migration and angiogenesis in nasopharyngeal carcinoma［J］. J Cancer, 2017, 8(18): 38873896. DOI: 10.7150/jca.19112. ［18］ Peng F, Li Q, Sun JY, et al. PFKFB3 is involved in breast cancer proliferation, migration, invasion and angiogenesis［J］. Int J Oncol, 2018, 52(3): 945-954. DOI: 10.3892/ijo.2018.4257. ［19］ Clem BF, O′Neal J, Tapolsky G, et al. Targeting 6phosphofructo2kinase (PFKFB3) as a therapeutic strategy against cancer［J］. Mol Cancer Ther, 2013, 12(8): 1461-1470. DOI: 10.1158/1535-7163.MCT-13-0097. ［20］ Telang S, Clem BF, Klarer AC, et al. Small molecule inhibition of 6phosphofructo2kinase suppresses T cell activation［J］. J Transl Med, 2012, 10: 95. DOI: 10.1186/1479-5876-10-95.

[1]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[3]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[4]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[5]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[6]	顾芳萌, 徐晨阳, 雷大鹏. 人工智能辅助电子喉镜检查在喉癌及喉癌前病变诊治中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(5): 303-307.
[7]	张文馨, 夏泠, 彭晋, 周福祥. 甲胎蛋白升高型胃肝样腺癌1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 312-315.
[8]	王昆, 周中新, 臧其威. 血清TGF-β1、VEGF水平对非小细胞肺癌患者单孔胸腔镜根治术后复发的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 198-203.
[9]	杨毫, 施贵冬, 张程城, 张跃, 张力文, 付茂勇. 信迪利单抗与替雷利珠单抗在进展期食管鳞状细胞癌新辅助治疗中的疗效及安全性对比[J]. 国际肿瘤学杂志, 2024, 51(4): 210-216.
[10]	姚益新, 沈煜霖. 血清SOCS3、TXNIP水平对肝细胞癌TACE治疗预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 217-222.
[11]	胡婷婷, 王越华. 电子鼻与线虫鼻——新型早期癌症筛查工具[J]. 国际肿瘤学杂志, 2024, 51(4): 223-226.
[12]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛. 索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[13]	严爱婷, 王翠竹, 刘春桂, 鲁小敏. 卡瑞利珠单抗与信迪利单抗治疗晚期非小细胞肺癌的临床疗效及安全性分析[J]. 国际肿瘤学杂志, 2024, 51(3): 137-142.
[14]	孙维蔚, 姚学敏, 王鹏健, 王静, 贾敬好. 基于血液学指标探讨免疫治疗晚期非小细胞肺癌预后因素及列线图构建[J]. 国际肿瘤学杂志, 2024, 51(3): 143-150.
[15]	钱晓涛, 石子宜, 胡格. Ⅲ~ⅣA期食管鳞状细胞癌根治性放化疗后行免疫检查点抑制剂维持治疗的真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(3): 151-156.